VG Life Sciences Inc. Announces Stock Ticker Symbol Change to “VGLS”

Symbol Change and Recent Name Change Reflect Company’s Evolution from R&D to Active Clinical Trials at Baylor Scott & White Health and Broader High Growth Life Sciences Operations

SAN MARINO, Calif.--(BUSINESS WIRE)--VG Life Sciences Inc. (OTC Pink: VRAL)(OTC Pink: VGLS) today announced that it will change its stock ticker symbol to “VGLS” from “VRAL” to reflect the company’s recent name change to VG Life Sciences Inc. from Viral Genetics, Inc. The new “VGLS” ticker symbol will be effective at the start of trading January 10, 2013.

The stock ticker symbol change follows the company’s recent name change and emphasizes the company’s evolution from a pure science / research and development entity into a company that is now focused on broader high-growth life sciences operations, including overseeing the company’s patented compounds in preIND ovarian cancer clinical trials at Baylor Scott & White Health, and additional opportunities with a broader reach into bio-fuels, agricultural applications and other high growth industries.

About VG Life Sciences Inc.

San Marino, California-based VG Life Sciences Inc., formerly known as Viral Genetics, discovers and develops drug therapies from two exclusively licensed platform technologies based upon its holdings of over 60 patents including Metabolic Disruption (MDT) and Targeted Peptides (TPT). A physician-initiated Phase I clinical trial of an MDT compound in combination with Nexavar™ on Stage III and IV ovarian cancer patients is ongoing at the Cancer Therapy and Research Center of The University of Texas Health Science Center at San Antonio. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. Founded in 1994, the biotech company is researching treatments for drug-resistant cancer, Lyme disease, Strep, Staph and Sepsis, and HIV/AIDS. For more information, visit www.viralgenetics.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This press release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences Inc. from time to time in its periodic reports, including statements about its subsidiary, VG Energy, Inc. None of VG Life Sciences Inc.’s drug compounds are currently approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While VG Life Sciences Inc. believes that the forward-looking statements and underlying assumptions are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of VG Life Sciences Inc. to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.’s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences Inc. or any other person that the objectives and plans of VG Life Sciences Inc. will be achieved. VG Life Sciences Inc. disclaims any obligation to update these forward-looking statements, except as required by law.